skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Lead Pb 212 TCMC-trastuzumab (Code C97500)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lead Pb 212 TCMC-trastuzumab

Definition: A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab conjugated with the bifunctional chelating agent TCMC ((1,4,7,10-Tetra-(2-Carbamoyl Methyl)-Cyclododecane), and radiolabeled with the alpha-emitting isotope lead Pb 212, with potential anti-tumor activity. Upon administration, the antibody moiety of lead Pb 212 TCMC-trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2); after internalization, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to the HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed on the cell surface of a variety of cancer cell types.

Display Name: Lead Pb 212 TCMC-trastuzumab

Label: Lead Pb 212 TCMC-trastuzumab

NCI Thesaurus Code: C97500 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL430248  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
[212]Pb TCMC-Herceptin
[212]Pb TCMC-trastuzumab
Lead Pb 212 TCMC-Herceptin
Lead Pb 212 TCMC-trastuzumab

External Source Codes: 
PDQ Closed Trial Search ID 703322
PDQ Open Trial Search ID 703322 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C97500
Contributing_Source CTRP
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom